Lupin's U.S. business has agreed to pay $30 million to settle antitrust claims brought by insurer Humana, according to a company filing made public on Friday. In the filing, Lupin maintained that it denies the allegations but is closing the matter with the insurer for the stated amount.
The settlement relates to a sprawling lawsuit initiated by Humana that lists 37 pharmaceutical companies as defendants. The complaint, as referenced in Lupin's disclosure, includes claims that certain companies unlawfully coordinated pricing and market control in the generics sector. One specific allegation cited in the case asserts that Lupin accepted reverse payments to delay the market introduction of a generic version of the diabetes medication Glumetza.
In its submission to the National Stock Exchange of India, Lupin reiterated that the settlement should not be interpreted as an admission of illegal activity. The company also said it had accounted for the $30 million payment in its reported earnings, indicating the amount had already been provided for in its financial statements.
Humana's action against the industry is broad in scope. Lupin's settlement follows a series of prior resolutions in the same matter - last year the insurer secured nearly $500 million in settlements from Sandoz, Sun Pharma, and Taro Pharmaceuticals, as noted in the company's filing and related disclosures.
For market participants and observers, the episode highlights ongoing legal scrutiny of generic drug competition and pricing practices. Lupin's public denial of wrongdoing, combined with its decision to settle and recognize the expense in earnings, leaves stakeholders with clarity on the immediate financial impact but not on any admission of liability.
Contextual note - The information above is drawn from Lupin's regulatory filing and public statements tied to the Humana suit. Where the filing indicates limitations or denials, those positions are reported as stated.